This session focuses on the nuances of selection of therapies for MASH and metabolic complications. Topics include the experience garnered following the US Food and Drug Administration approval of resmetirom and new therapeutic agents currently in phase 3 clinical trials.
This interactive session provides clinicians a unique opportunity to both learn and practice evidence-based skills for handling tough conversations they may experience with patients and families. Presenters first review evidence-based approaches for common communication challenges (eg, delivering serious news, handling uncertainty, responding to emotions), discuss key phrases, and model ideal and less-than-ideal encounters. Participants then break into small groups to practice core serious illness communication skills using standardized patient encounters and receive in-the-moment feedback from experts. Presenters lead a group reflection to conclude the session.
Emerging evidence has shed light on the complexity of the gut microbiome and its influence on the tumor immune microenvironment, tumorigenesis, and therapeutic responses. Sequencing studies have examined the differential microbiota composition between healthy individuals and patients with cirrhotic liver disease. Recent studies have shown the influence of the gut microbiome on liver cancer development and progression. Thereby, the gut microbiome represents a potential target for therapeutic intervention, and its composition may potentially serve as a predictive biomarker for enhanced responses to immunotherapy.<strong> </strong>In this session, experts review recent advances in our understanding of: (1) the role of the gut microbiome in influencing liver cancer tumorigenesis and progression; (2) the effect of the gut microbiome on immunotherapy sensitivities; (3) the relationship of the gut microbiome with the immune system; and (4) the development of novel therapeutics.
Experts examine and discuss the latest information regarding the management of special populations with chronic HCV infection. The unique and key populations addressed in the session include men who have sex with men, transgender individuals, persons in carceral facilities, pregnant individuals, children, and people who inject drugs.
Cardiovascular disease is the leading cause of death among patients with MASH. The mechanisms by which liver fibrosis due to MASH promotes cardiovascular disease are not clear. Moreover, emerging data suggest that cardiac disease may promote liver fibrosis progression. In this session, speakers provide a clinical overview of the association between MASH-related fibrosis/cirrhosis and cardiovascular disease, and dissect potential underlying mechanisms.<br />
Cosponsored by the Inclusion and Diversity Committee, the Women's Initiatives Committee, and the LGBTQ Taskforce, the program centers on academic advancement, promotion, and tenure for under-represented groups in hepatology. Under-represented groups—which can vary by context and geography—may identify by race, ethnicity, gender identity or sexual orientation, disability, etc. Speakers' presentations focus on various aspects of academic advancement, including talks aimed at junior faculty and trainees regarding academic advancement and promotion for clinical track faculty, and academic advancement and tenure for research and basic science oriented faculty. Barriers to academic rank promotion for nurse practitioner and physician associate faculty are discussed as well as the need for a consistent framework for academic advancement for across institutions. All are welcome.
Hosted by the AASLD Training and Workforce Committee, the goal of this session is to combine fun, friends (new and old), and facts. Attendees are asked to join a team at a table and get ready to answer hepatology-related trivia questions. This highly interactive session combines foundational and advanced hepatology trivia in a fast-paced trivia format, engaging attendees and encouraging some lighthearted competition with networking baked in. And – there will be prizes! <br />
<br />
<strong>Slido: <a href="https://app.sli.do/event/oTBx2M1P5cyqKmzEv7tu36">https://app.sli.do/eve…;
Gain insights into the current state of liver transplantation management worldwide. This segment provides updates on the Organ Procurement and Transplantation Network (OPTN) modernization project; explores international strategies for organ allocation (both deceased and living donations); and engages in a critical discussion of the advantages and challenges of posttransplant data reporting.
Experts review updates in the field for the prognostication and management of intrahepatic cholestasis of pregnancy (ICP). Speakers lead a case-based discussion about challenging ICP cases and share approaches to management from ursodiol to ileal bile acid transporter (IBAT) inhibitor treatment. Topics include the association of chronic liver disease—including primary biliary cholangitis, hepatitis C, autoimmune liver disease, and cirrhosis—with the development of ICP, and the relevance of genetic testing for individuals with ICP.<br />
<br />
Gain insights into the global aspects of acute liver failure by exploring the epidemiology, therapies, and preventive approaches in various regions of the world, as well as differentiating acute liver failure from acute-on-chronic liver failure. Learn from leading experts from various regions of the world who present on specific aspects of acute liver failure using a case-study approach. This session is co-endorsed by our sister societies: the Latin American Association for the Study of the Liver, the Asian Pacific Association for the Study of the Liver, the European Association for the Study of the Liver, and the Society on Liver Disease in Africa.